CO6321263A2 - NEW DERIVATIVES OF PHENYLIMIDAZOL AS INHIBITORS OF THE ENZYME PDE10A - Google Patents
NEW DERIVATIVES OF PHENYLIMIDAZOL AS INHIBITORS OF THE ENZYME PDE10AInfo
- Publication number
- CO6321263A2 CO6321263A2 CO10159483A CO10159483A CO6321263A2 CO 6321263 A2 CO6321263 A2 CO 6321263A2 CO 10159483 A CO10159483 A CO 10159483A CO 10159483 A CO10159483 A CO 10159483A CO 6321263 A2 CO6321263 A2 CO 6321263A2
- Authority
- CO
- Colombia
- Prior art keywords
- provides
- subject
- compound
- formula
- effective amount
- Prior art date
Links
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- ZCUJYXPAKHMBAZ-UHFFFAOYSA-N 2-phenyl-1h-imidazole Chemical class C1=CNC(C=2C=CC=CC=2)=N1 ZCUJYXPAKHMBAZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 4
- 239000003937 drug carrier Substances 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención se dirige a compuestos que son inhibidores de la enzima PDE10A. La invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto de la invención y un portador farmacéuticamente aceptable. La presente invención también proporciona procesos para la preparación de los compuestos de fórmula I. La presente invención proporciona además un método para tratar un sujeto que sufre un trastorno neurodegenerativo, que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto de fórmula I. La presente invención asimismo proporciona un método para tratar un sujeto que sufre una adicción a las drogas, que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto de fórmula I. La presente invención también proporciona un método para tratar un sujeto que sufre un trastorno psiquiátrico, que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto de fórmula I.This invention is directed to compounds that are inhibitors of the PDE10A enzyme. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method for treating a subject suffering from a neurodegenerative disorder, which comprises administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method for treating a subject suffering from a drug addiction, which comprises administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method for treating a subject suffering from a psychiatric disorder. , which comprises administering to the subject a therapeutically effective amount of a compound of formula I.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200800855 | 2008-06-20 | ||
| DKPA200900402 | 2009-03-24 | ||
| DKPA200900519 | 2009-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6321263A2 true CO6321263A2 (en) | 2011-09-20 |
Family
ID=40902594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10159483A CO6321263A2 (en) | 2008-06-20 | 2010-12-20 | NEW DERIVATIVES OF PHENYLIMIDAZOL AS INHIBITORS OF THE ENZYME PDE10A |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8841297B2 (en) |
| EP (1) | EP2318394B1 (en) |
| JP (1) | JP5930714B2 (en) |
| KR (3) | KR101703938B1 (en) |
| CN (2) | CN102124002B (en) |
| AR (1) | AR072199A1 (en) |
| AU (1) | AU2009259209B2 (en) |
| BR (1) | BRPI0915383B8 (en) |
| CA (1) | CA2728335C (en) |
| CL (2) | CL2010001467A1 (en) |
| CO (1) | CO6321263A2 (en) |
| CY (1) | CY1115001T1 (en) |
| DK (1) | DK2318394T3 (en) |
| EA (2) | EA018880B1 (en) |
| ES (1) | ES2456349T3 (en) |
| HR (1) | HRP20140232T1 (en) |
| IL (1) | IL209834A (en) |
| MX (1) | MX2010014136A (en) |
| MY (1) | MY152949A (en) |
| NZ (1) | NZ589926A (en) |
| PL (1) | PL2318394T3 (en) |
| PT (1) | PT2318394E (en) |
| RS (2) | RS53226B (en) |
| SI (1) | SI2318394T1 (en) |
| TW (1) | TWI501965B (en) |
| WO (1) | WO2009152825A1 (en) |
| ZA (1) | ZA201100109B (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA102693C2 (en) | 2008-06-20 | 2013-08-12 | Х. Луннбек А/С | Phenylimidazole derivatives as pde10a enzyme inhibitors |
| TWI501965B (en) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | Novel phenylimidazole derivatives as pde10a enzyme inhibitors |
| US8133897B2 (en) * | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
| TWI481607B (en) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 2-arylimidazole derivatives as PDE10A enzyme inhibitors |
| TWI485151B (en) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors |
| NZ601967A (en) | 2010-03-12 | 2015-03-27 | Omeros Corp | Pde10 inhibitors and related compositions and methods |
| US8410117B2 (en) * | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
| EP2576540B1 (en) | 2010-05-26 | 2019-09-04 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| TW201215607A (en) | 2010-07-02 | 2012-04-16 | Lundbeck & Co As H | Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor |
| TW201206935A (en) | 2010-07-16 | 2012-02-16 | Lundbeck & Co As H | Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor |
| EP2602255B1 (en) * | 2010-08-04 | 2017-04-26 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
| JP5760085B2 (en) * | 2010-08-04 | 2015-08-05 | 武田薬品工業株式会社 | Fused heterocyclic compounds |
| HUE025511T2 (en) | 2010-11-10 | 2016-04-28 | H Lundbeck As | Radiolabelled phenylimidazole-based ligands |
| JO3089B1 (en) * | 2010-11-19 | 2017-03-15 | H Lundbeck As | Imidazole derivatives as inhibitors of PDE10A enzymes |
| US8552045B2 (en) | 2010-11-19 | 2013-10-08 | H. Lundbeck A/S | Tricyclic imidazole compounds as PDE10 inhibitors |
| US8349824B2 (en) * | 2010-12-07 | 2013-01-08 | Hoffmann-La Roche Inc. | Triazolopyridine compounds |
| CA2824047C (en) | 2011-01-11 | 2019-06-18 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| US9540379B2 (en) * | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| US8772316B2 (en) | 2011-02-18 | 2014-07-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) |
| WO2013005798A1 (en) * | 2011-07-06 | 2013-01-10 | 持田製薬株式会社 | Novel nitrogenated heterocyclic ring derivative |
| WO2013045607A1 (en) | 2011-09-30 | 2013-04-04 | H. Lundbeck A/S | Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors |
| WO2013050527A1 (en) | 2011-10-05 | 2013-04-11 | H. Lundbeck A/S | Quinazoline derivatives as pde10a enzyme inhibitors |
| AR089361A1 (en) * | 2011-12-21 | 2014-08-20 | Lundbeck & Co As H | DERIVATIVES OF QUINOLINE AS INHIBITORS OF THE ENZYME PDE10A |
| WO2013127817A1 (en) | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
| KR101666293B1 (en) * | 2012-05-30 | 2016-10-13 | 에프. 호프만-라 로슈 아게 | Triazolo compounds as pde10 inhibitors |
| EP2861596B1 (en) | 2012-06-19 | 2019-03-20 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| WO2014100533A1 (en) | 2012-12-21 | 2014-06-26 | Bristol-Myers Squibb Company | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS |
| TR201904614T4 (en) * | 2013-02-27 | 2019-05-21 | Mochida Pharm Co Ltd | Novel pyrazole derivative. |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| WO2015164508A1 (en) | 2014-04-23 | 2015-10-29 | Dart Neuroscience, Llc | Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors |
| NZ716462A (en) | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| PL408251A1 (en) * | 2014-05-19 | 2015-11-23 | Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością | Condensed derivatives of triazole as phosphodiesterase 10A inhibitors |
| EP3215508A1 (en) * | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Substituted 5-methyl-[1, 2, 4]triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors |
| BR112017022936A2 (en) | 2015-04-24 | 2018-07-17 | Omeros Corp | pde10 inhibitors and related compositions and methods |
| CA3003611C (en) | 2015-11-04 | 2022-11-01 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| WO2020094590A1 (en) | 2018-11-06 | 2020-05-14 | H. Lundbeck A/S | 5,8-dimethyl-2-[2-(1-methyl-4-phenyl-1h-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyrazine hemiadipate |
| WO2020094591A1 (en) | 2018-11-06 | 2020-05-14 | H. Lundbeck A/S | Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia |
| BR112020013697A2 (en) | 2018-11-06 | 2020-12-01 | H. Lundbeck A/S | compounds to treat negative symptoms and cognitive impairments |
| CN110981813A (en) * | 2019-12-19 | 2020-04-10 | 西安近代化学研究所 | Synthetic method of 2-cyano-5-aryl-1H-imidazole compound |
| CN111100071A (en) * | 2019-12-19 | 2020-05-05 | 西安近代化学研究所 | Method for synthesizing 2-cyano-5-aryl-1H-imidazole compound |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036840A (en) | 1972-06-07 | 1977-07-19 | Icn Pharmaceuticals | 2-Substituted-s-triazolo[1,5a]pyrimidines |
| DE10230605A1 (en) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituted imidazotriazines |
| WO2005003129A1 (en) * | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolodihydroisoquinolines as pde10 inhibitors |
| BRPI0507839A (en) * | 2004-02-18 | 2007-05-08 | Pfizer Prod Inc | tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
| US7368467B2 (en) | 2004-03-08 | 2008-05-06 | Wyeth | Ion channel modulators |
| US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| NL2000397C2 (en) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclic heteroaryl compounds as PDE10 inhibitors. |
| CA2643963A1 (en) * | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| CA2654394A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| EP2173728A2 (en) | 2007-07-17 | 2010-04-14 | Amgen Inc. | Heterocyclic modulators of pkb |
| EA201000201A1 (en) | 2007-08-10 | 2010-12-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | NITROGEN-CONTAINING BICYCLIC CHEMICALS FOR THE TREATMENT OF VIRAL INFECTIONS |
| US8133897B2 (en) | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
| UA102693C2 (en) | 2008-06-20 | 2013-08-12 | Х. Луннбек А/С | Phenylimidazole derivatives as pde10a enzyme inhibitors |
| TWI501965B (en) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | Novel phenylimidazole derivatives as pde10a enzyme inhibitors |
-
2009
- 2009-06-15 TW TW098119876A patent/TWI501965B/en not_active IP Right Cessation
- 2009-06-19 MX MX2010014136A patent/MX2010014136A/en active IP Right Grant
- 2009-06-19 KR KR1020107028654A patent/KR101703938B1/en not_active Expired - Fee Related
- 2009-06-19 PL PL09765461T patent/PL2318394T3/en unknown
- 2009-06-19 BR BRPI0915383A patent/BRPI0915383B8/en not_active IP Right Cessation
- 2009-06-19 PT PT97654610T patent/PT2318394E/en unknown
- 2009-06-19 SI SI200930879T patent/SI2318394T1/en unknown
- 2009-06-19 JP JP2011513878A patent/JP5930714B2/en not_active Expired - Fee Related
- 2009-06-19 HR HRP20140232AT patent/HRP20140232T1/en unknown
- 2009-06-19 CA CA2728335A patent/CA2728335C/en not_active Expired - Fee Related
- 2009-06-19 WO PCT/DK2009/050134 patent/WO2009152825A1/en not_active Ceased
- 2009-06-19 EA EA201170061A patent/EA018880B1/en not_active IP Right Cessation
- 2009-06-19 DK DK09765461.0T patent/DK2318394T3/en active
- 2009-06-19 EP EP09765461.0A patent/EP2318394B1/en active Active
- 2009-06-19 KR KR1020177002859A patent/KR20170016523A/en not_active Ceased
- 2009-06-19 AR ARP090102239A patent/AR072199A1/en active IP Right Grant
- 2009-06-19 CN CN200980132027.3A patent/CN102124002B/en not_active Expired - Fee Related
- 2009-06-19 AU AU2009259209A patent/AU2009259209B2/en not_active Ceased
- 2009-06-19 NZ NZ589926A patent/NZ589926A/en not_active IP Right Cessation
- 2009-06-19 RS RS20140135A patent/RS53226B/en unknown
- 2009-06-19 ES ES09765461.0T patent/ES2456349T3/en active Active
- 2009-06-19 KR KR1020177034302A patent/KR102025487B1/en not_active Expired - Fee Related
- 2009-06-19 MY MYPI20106011 patent/MY152949A/en unknown
-
2010
- 2010-06-17 EA EA201270046A patent/EA021410B1/en not_active IP Right Cessation
- 2010-06-17 RS RS20140700A patent/RS53704B1/en unknown
- 2010-06-17 CN CN201080037331.2A patent/CN102482262B/en not_active Expired - Fee Related
- 2010-06-17 US US13/378,405 patent/US8841297B2/en not_active Expired - Fee Related
- 2010-12-07 IL IL209834A patent/IL209834A/en active IP Right Grant
- 2010-12-17 CL CL2010001467A patent/CL2010001467A1/en unknown
- 2010-12-20 CO CO10159483A patent/CO6321263A2/en active IP Right Grant
-
2011
- 2011-01-04 ZA ZA2011/00109A patent/ZA201100109B/en unknown
- 2011-12-16 CL CL2011003205A patent/CL2011003205A1/en unknown
-
2014
- 2014-03-28 CY CY20141100233T patent/CY1115001T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6321263A2 (en) | NEW DERIVATIVES OF PHENYLIMIDAZOL AS INHIBITORS OF THE ENZYME PDE10A | |
| CO6612246A2 (en) | 2-arylimidazole derivatives as enzyme inhibitors pde10a | |
| DOP2012000165A (en) | HETEROAROMATIC PHENYLIMIDAZOL DERIVATIVES AS ENZYME PDE10A INHIBITORS | |
| DOP2012000169A (en) | DERIVATIVES OF ARIL TRIAZOL HETEROAROMATICOS AS INHIBITORS OF ENZYME PDE10A | |
| ECSP13012698A (en) | IMIDAZOL DERIVATIVES AS INHIBITORS OF THE ENZYME PDE10A | |
| MX2019014982A (en) | DERIVATIVES OF 7H-IMIDAZO [1-5-A] PIRAZIN-8-ONA AS INHIBITORS OF PHOSPHODIESTERASE 9 (PDE9); AND THE USE OF THE SAME IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS. | |
| ECSP14015609A (en) | PDE9 INHIBITORS WITH BASIC IMIDAZOTRIAZINONE STRUCTURE | |
| UA102693C2 (en) | Phenylimidazole derivatives as pde10a enzyme inhibitors | |
| DOP2013000108A (en) | IMIDAZOL DERIVATIVES AS INHIBITORS OF THE ENZYME PDE10A | |
| CY1116689T1 (en) | Imidazole derivatives as inhibitors of the PDE10A enzyme | |
| TN2013000200A1 (en) | Imidazole derivatives as pde 10a enzyme inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |